Key Highlights

  • Context Therapeutics (NASDAQ:CNTX) posted a second quarter 2026 net loss of USD 14.56 million, a 65% jump from USD 8.83 million, or USD 0.15 per share. Cash stood at USD 43 million on June 30, 2026.
  • Management indicated that this cash covers operations through the fourth quarter of 2027. The lead drug, CTIM-76, earned FDA Fast Track status in April 2026, and a Phase 1b expansion is slated to begin in the first quarter of 2027.
  • Published coverage cited a USD 0.69 close on August 5, 2026, followed by an overnight decline of 23.06% to USD 0.53. These are single-source numbers, so we treat them as rough estimates.
  • Market data on the screener place CNTX at USD 0.20, up 6.82% in the latest session on 1.29 million shares, for a Market Value of USD 18.56 million. Treat those screener numbers as unconfirmed.

A Loss That Widened With the Pipeline

Context reported second quarter numbers in early August 2026. The loss grew 65% to USD 14.56 million as research spending increased, and the company held USD 43 million at June 30. Management said funding carries operations through the fourth quarter of 2027. CTIM-76, a bispecific antibody aimed at platinum resistant ovarian cancer, won FDA Fast Track Designation in April 2026. A second candidate, CT-202, received Australian approval to start a first in human study, with early readouts expected in the second half of 2027. Context Therapeutics (NASDAQ:CNTX) also dropped CT-95 so it could concentrate its resources.

From USD 0.69 to USD 0.20

Penny stock screens pick up low priced shares, and Context fits that profile. Published coverage listed a USD 0.69 close on August 5, 2026, up 11.45%, before an overnight drop of 23.06% to USD 0.53 following the results. The screener price of USD 0.20 sits about 71% under USD 0.69, which is our own calculation using one single-source figure and one unconfirmed screener figure. We have found no filing that explains the decline since August. Screener data put the market value at USD 18.56 million, far below the USD 43 million of cash reported at June 30, although cash has been burned since then, so the comparison is only a rough guide. The company also revised its BioAtla license in May 2026, dropping future milestone and Royalty payments.

Risks and What to Watch

Only a few trades can move a stock this size, bid and ask spreads may be wide, and a quoted gain such as 6.82% can disappear quickly, so it should not be taken as a rebound. Cancer drugs in clinical stages Fail frequently, and Phase 1 results from a handful of patients rarely predict approval. A financing before the close of 2027 looks likely and would dilute shareholders. Trading under USD 1.00 can bring a Nasdaq compliance notice, although we have not seen one. Investors should monitor when the first patient gets dosed in the CT-202 trial, the start of the CTIM-76 expansion in the first quarter of 2027 and any Capital raise. Management also indicated that early CT-202 data are not expected until the second half of 2027, so near-term clinical catalysts may be scarce.

Where Things Stand

Context could rebound if early cancer results are encouraging, or if investors conclude that a USD 18.56 million market value understates USD 43 million of June cash, but no filing guarantees either outcome. The share price has dropped about 71% from the August close, using mixed sources. Context Therapeutics (NASDAQ:CNTX) has funding into late 2027 and two clinical programmes, yet dilution, trial risk and thin trading keep it a speculative stock.